Skip to main content
Journal cover image

Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.

Publication ,  Journal Article
Vardi, M; Burke, DA; Bangalore, S; Pencina, MJ; Mauri, L; Kandzari, DE; Leon, MB; Cutlip, DE
Published in: Catheter Cardiovasc Interv
December 1, 2013

OBJECTIVE: To assess long-term outcomes of Endeavor Zotarolimus-eluting stent (E-ZES) implantation in patients with diabetes mellitus (DM). BACKGROUND: Patients with DM and coronary artery disease have lower restenosis with drug-eluting stent (DES) compared with bare-metal stents. Recent data suggest that the E-ZES is inferior to other DES in this population. METHODS: Patient-level data for 601 patients with DM from the ENDEAVOR III and ENDEAVOR IV trials were pooled, of which 337 were treated with E-ZES and 264 were treated with other DES. The primary outcome was target vessel failure (TVF) in the course of 5 years. Outcomes are reported as rates using Kaplan-Meier (KM) survival method and differences between E-ZES and other stent types (sirolimus-eluting stent or paclitaxel-eluting stent) were compared using the log-rank statistic. The independent effect of stent type on TVF was assessed using Cox proportional hazards regression. RESULTS: Baseline characteristics were similar between the groups. Five-year TVF KM rate estimate was numerically lower for E-ZES, but the difference did not reach statistical significance (20.2 vs. 26.9%, P = 0.065). The 5-year KM rate estimates of major adverse cardiac events (17.7 vs. 26.6%, P = 0.012), death (7.6 vs. 15.0%, P = 0.004), and myocardial infarction (1.3 vs. 5.1%, P = 0.011) were also lower for E-ZES versus other DES. CONCLUSIONS: Patients with DM implanted with E-ZES have favorable long-term outcomes compared to first-generation DES. Long-term performance of DES should be assessed routinely and may differ from initial performance.

Duke Scholars

Published In

Catheter Cardiovasc Interv

DOI

EISSN

1522-726X

Publication Date

December 1, 2013

Volume

82

Issue

7

Start / End Page

1031 / 1038

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Sirolimus
  • Risk Factors
  • Prosthesis Design
  • Prospective Studies
  • Proportional Hazards Models
  • Percutaneous Coronary Intervention
  • Paclitaxel
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vardi, M., Burke, D. A., Bangalore, S., Pencina, M. J., Mauri, L., Kandzari, D. E., … Cutlip, D. E. (2013). Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. Catheter Cardiovasc Interv, 82(7), 1031–1038. https://doi.org/10.1002/ccd.25045
Vardi, Moshe, David A. Burke, Sripal Bangalore, Michael J. Pencina, Laura Mauri, David E. Kandzari, Martin B. Leon, and Donald E. Cutlip. “Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.Catheter Cardiovasc Interv 82, no. 7 (December 1, 2013): 1031–38. https://doi.org/10.1002/ccd.25045.
Vardi M, Burke DA, Bangalore S, Pencina MJ, Mauri L, Kandzari DE, et al. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1031–8.
Vardi, Moshe, et al. “Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.Catheter Cardiovasc Interv, vol. 82, no. 7, Dec. 2013, pp. 1031–38. Pubmed, doi:10.1002/ccd.25045.
Vardi M, Burke DA, Bangalore S, Pencina MJ, Mauri L, Kandzari DE, Leon MB, Cutlip DE. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1031–1038.
Journal cover image

Published In

Catheter Cardiovasc Interv

DOI

EISSN

1522-726X

Publication Date

December 1, 2013

Volume

82

Issue

7

Start / End Page

1031 / 1038

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Sirolimus
  • Risk Factors
  • Prosthesis Design
  • Prospective Studies
  • Proportional Hazards Models
  • Percutaneous Coronary Intervention
  • Paclitaxel
  • Middle Aged